C-Suite Spotlight Announces Top 25 Pharmaceutical Executives of 2023
NEW YORK (PRWEB) June 28, 2023 -- C-Suite Spotlight is pleased to announce The Top 25 Pharmaceutical Executives of 2023. The pharmaceutical industry has come a long way since the early days when apothecaries and pharmacies offered traditional remedies as far back as the middle ages. Some of the earliest organizations to pop up include Merck and GlaxoSmithKline, whose roots can be traced back to the 17th and 18th centuries respectively. More recently, the Covid-19 pandemic put the global pharmaceuticals industry into the spotlight with the world collectively working towards breakthroughs in order to prevent a permanent cycle of lockdowns and crises. Following in the tradition of many great scientific minds, the leaders on this year’s list play a vital role in the discovery, development, production, and distribution of medicines and healthcare products that improve lives for people around the globe.
Among the exceptional men and women featured in this year's list is Karen Lynch, who serves as President and CEO of CVS Health, where she leads more than 300,000 colleagues who touch the lives of 100 million people across the U.S. Additionally, Jean-Jacques Bienaimé, the Chairman and CEO of BioMarin, has impressively grown his company's valuation from around $450 million in 2005 to approximately $14 billion in 2021. Another prominent figure is Dr. Yvonne Greenstreet, Director and CEO of Alnylam, where she leverages her more than 25 years of experience in the biopharmaceutical industry–including previously serving as Head of Medicines Development at Pfizer, where she led a rapidly growing $16 billion division.
Please join us in recognizing the accomplishments of The Top 25 Pharmaceutical Executives of 2023.
David Ricks (Eli Lilly), Joaquin Duato (Johnson & Johnson), Robert Davis (Merck), Richard Gonzalez (AbbVie), Dr. Albert Bourla (Pfizer), Giovanni Caforio (Bristol Myers Squibb), Robert Bradway (Amgen), Daniel O’Day (Gilead Sciences), Reshma Kewalramani (Vertex Pharmaceuticals), Leonard Schleifer (Regeneron Pharmaceuticals), Kristin Peck (Zoetis), Joe Almeida (Baxter), Adam Schechter (LabCorp), Jean-Jacques Bienaimé (BioMarin Pharmaceutical), Hervé Hoppenot (Incyte), Charles Kummeth (Bio-Techne), Douglas Ingram (Sarepta Therapeutics), Ying Huang (Legend Biotech), Scott Smith (Viatris), Robert Blum (Cytokinetics), Emil Kakkis (Ultragenyx), Warren Huff (Reata Pharmaceuticals), John Leonard (Intellia Therapeutics), Rami Elghandour (Arcellx), and Chris Gibson (Recursion).
To view the full list visit https://csuitespotlight.com/2023/06/26/the-top-25-pharmaceutical-executives-of-2023/
About C-Suite Spotlight
C-Suite Spotlight provides executives with a broad range of topics and areas of interest including leadership, innovation, mindset, collaboration, team building, wellness, among many other areas. C-Suite Spotlight and its affiliates circulate its content to over 30,800 individuals including executives, senior professionals, investors, and media influencers across major industries.
Editor, C-Suite Spotlight, https://csuitespotlight.com/, 1 609-365-7014, [email protected]
Share this article